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Abstract 
Abstract: Review on Osteochondroma, with data on 
clinics, and the genes involved. 
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Identity 
Osteochondroma (osteocartilaginous exostosis) is a 
benign cartilage capped bony neoplasm arising on 
the external surface of bone containing a marrow 
cavity that is continuous with that of the underlying 
bone. It arises in bones preformed by endochondral 
ossification and the most common site of 
involvement is the metaphyseal region of the long 
bone of the limbs, like the distal femur, upper 
humerus, upper tibia and fibula. They also frequently 
occur in the flat bones, in particular the ilium and 
scapula. Osteochondromas can occur as a solitary 
lesion (solitary osteochondromas) or within the 
context of Multiple Osteochondromas (MO). The 
literature indicates slight male sex predominance 
(male/female ratio 1.5:1). Most osteochondromas 
are prone to arise in the first three decades of life. 
Osteochondromas hardly occur in the craniofacial 
bones. This might be explained by the fact that these 
bones are not formed by endochondral ossification. 
Clinics and pathology 
Epidemiology 
Osteochondromas are the most common benign bone 
tumors.  
They represent 35% of the benign and 8% of all bone 
tumours, although this is probably an 
underestimation since the majority are 
asymptomatic.  
Approximately 15% of patients with 
osteochondromas have multiple osteochondromas 
(MO), which has an estimated incidence of 1 in 
50,000. 
Clinics 
The growth of the osteochondroma ceases at skeletal 
maturation or shortly thereafter.  
Patients may have a swelling causing symptoms 
related to the location and site of the lesion such as 
mechanical obstruction, nerve impingement, 
pseudoaneurysm of an overlying vessel, fracture at 
the stalk of the lesion, or the formation of a bursa 
over the osteochondroma. However most lesions are 
asymptomatic and found accidentally.  
The most serious complication is malignant 
transformation towards secondary peripheral 
chondrosarcoma, which is estimated to occur in <1% 
of solitary cases and up to 5% of MO cases. 
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Figure 1: Histological appearance of an osteochondroma. A perichondrium covers the cartilage cap. The cap merges into the 
underlying spongiosa, where the chondrocytes are arranged according to an epiphyseal growth plate. 
 
Pathology 
Pedunculated osteochondromas contain a stalk and 
are long and slender, while sessile ones are flat. 
Many osteochondromas are cauliflower shaped 
(figure 1). A non-neoplastic fibrous perichondrium 
covers the cartilage cap and is continuous with the 
periosteum of the underlying bone. The cartilage cap 
is less than 2 cm thick and this is decreasing with 
age. A thick (1.5-2 cm) unmineralized and irregular 
cap may indicate malignant transformation of the 
tumor. The cap covers the entire elevated surface of 
a sessile tumor, while it only covers the distal part of 
a pedunculated one. The cartilage cap merges into 
the underlying spongiosa. Here the chondrocytes are 
arranged according to an epiphyseal growth plate. A 
typical benign chondrocyte has a single small 
nucleus. During active bone growth, binucleated 
chondrocytes may be seen in benign tumors. The 
spongiosa of the stalk is continuous with the 
underlying cancellous bone. Fractures within the 
stalk may produce fibroblastic proliferation and even 
new bone formation. A bursa may develop over the 
osteochondroma and is usually attached to the 
perichondrium of the cap. The bursal wall is lined by 
synovium that may show inflammatory changes. 
Treatment 
The low rate of malignant transformation is 
insufficient reason for resection. Osteochondromas 
are usually removed for cosmetic reasons, when 
symptoms of pain, limitation of motion, or 
impingement on adjacent structures such as nerves 
and blood vessels occur, or when roentogenographic 
features or an abnormal increase in tumor size 
suggest progression towards malignancy. When 
surgical resection is needed, the entire lesion should 
be removed, including the complete cartilaginous 
cap, to avoid recurrence. Multiple recurrence or 
recurrence in a well-excised lesion should raise 
suspicion of malignancy. 
Evolution 
Until recently, there has been a lot of debate about 
whether an osteochondroma is a developmental 
disorder or a true neoplasm. It was for long 
considered to be a perversion in the direction of bone 
growth. However, recent studies have shown 
osteochondroma to be a true neoplasm, since loss of 
heterozygosity (LOH) and aneuploidy have been 
found in osteochondromas, indicating a clonal origin 
of the cartilage cap. The cell of origin of 
osteochondroma development remains a point of 
debate among researchers, as research by different 
groups indicates either a proliferating cell of the 
growth plate or mesenchymal stem cells of the 
periochondrium as the cell of origin. 
Prognosis 
Complete excision of osteochondroma is usually 
curative. Failure to remove the entire cartilaginous 
cap or its overlying periosteum is the basis for most 
recurrences. Recurrence could also suggest 
malignancy. 
Cytogenetics 
Both sporadic and multiple osteochondromas are 
linked to mutations in the genes for Exostosin-1 
(EXT1 ,11p12-p11) and -2 ( EXT2  8q24.11-24.13). 
A mutation in either of these genes is detected in 
around 80% of all MO patients, with most MO 
families showing mutations in EXT1. Currently, 
over 650 of these mutations are registered in the 
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Multiple Osteochondroma Mutation Database 
(MOdb, url: www.lovd.nl/ext1 and 
www.lovd.nl/ext2). 
Genes involved and 
proteins 
Research identified nonsense, frame shift and splice-
site mutations as the most common mutations in the 
EXT genes, with mutations in EXT1 causing a more 
severe disease phenotype. These heterozygous 
mutations by themselves are, however, insufficient 
to trigger osteochondroma development, as 
heterozygous Ext +/- or Ext2 +/- mutant mice were 
found to be largely normal. In MO-related 
osteochondroma, additional identified genetic 
changes include LOH and aneuploidy. LOH causes 
loss of the remaining wild-type allele, resulting in 
EXT1 or EXT2-null cells. For osteochondroma to 
develop, it is sufficient to have complete loss of 
EXT1 or EXT2 in only a small number of cells, as 
research showed that loss of EXT1 in a few 
chondrocytes resulted in osteochondromas in mice, 
mimicking the human disease phenotype.   
In addition, EXT mutations were described to induce 
cytoskeletal abnormalities (altered actin distribution) 
in osteochondroma chondrocytes.Loss of EXT1 or 
EXT2 has severe consequences for the biosynthesis 
of heparan sulfate (HS), since the EXT genes encode 
proteins involved in this process. The EXT proteins 
are both required to form a functional complex, 
explaining why mutations in either of these genes 
can cause osteochondroma formation. The protein 
complex is responsible for the assembly of HS 
chains onto HS proteoglycans (HSPGs). HSPGs are 
large macromolecules composed of heparan sulphate 
glycosaminoglycan chains linked to a core protein. 
Examples include syndecan, glypican, and perlecan.  
HSPGs have many developmental and physiological 
functions, including their ability to interact with 
signalling proteins like fibroblast growth factors 
(FGF), bone-morphogenic proteins (BMP) and 
hedgehog (Hh) morphogens. HS decreases BMP 
signalling, but has the opposite effect on FGF 
signalling. This has hypothesized to lead to an 
increase in chondrogenic differentiation and 
consequently osteochondroma development 
In osteochondroma, there is so-called loss of cell 
polarity. In the normal growth plate, chondrocyte 
primary cilia are highly organized and found to be 
oriented parallel to the longitudinal axis of the bone. 
In osteochondroma, cilia were found to be randomly 
located along the growth axis of the tumor and 
absence of alignment was found with either the 
osteochondroma growth direction or growth 
direction of the host bone. Primary cilia have been 
shown to mediate Indian hedgehog (Ihh) signalling. 
IHh (Indian hedgehog) is very important in normal 
bone development, coordination of chondrocyte 
proliferation, differentiation and osteoblast 
differentiation. Furthermore, Ihh signalling plays a 
role in formation of the bone collar, which is the 
precursor of the cortical region of long bones. Ihh is 
synthesized by chondrocytes leaving the 
proliferative pool and early hypertrophic 
chondrocytes. Its diffusion generates a gradient 
within the growth plate, coordinating cell 
proliferation and differentiation. In osteochondroma, 
Ihh signalling was found to be homogeneous, 
suggestive of cell autonomous signalling, removing 
the need for correct orientation of the cilium. 
Regarding the bone collar formation, research 
showed that Ihh-null mice do not have a bone collar 
while overexpression of Ihh induced bone collar 
formation. Disturbances in Ihh signalling may 
therefore lead to a defect in the bone collar, which 
may in turn lead to osteochondroma formation.  
Research indicates that the cartilage cap of the 
osteochondroma is a mix of wild-type and mutant 
cells. It is hypothesized that the wild-type cells 
acquire other mutations, leading to malignant 
transformation and tumor growth. Malignant 
transformation of osteochondroma is characterized 
at the DNA level by chromosomal instability, as well 
as loss or inactivation of the CDKN2A and TP53 
tumor suppressor genes. The proteins encoded by 
these genes are involved in the cell cycle, among 
others, and their loss has shown to lead to 
deregulation of the cell cycle and transformation of 
osteochondromas into peripheral chondrosarcomas. 
This was shown by a thickened cartilaginous cap, 
lobules of cartilage growth beyond the cap and 
increased cellularity in mice in which these genes 
had been genetically disrupted. 
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